Business description: Constellation Pharmaceuticals, Inc.

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Number of employees: 154

Sales by Activity: Constellation Pharmaceuticals, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD)

Geographical breakdown of sales: Constellation Pharmaceuticals, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD)

Executive Committee: Constellation Pharmaceuticals, Inc.

Manager TitleAgeSince
President - -
Investor Relations Contact - -
Corporate Officer/Principal - 31/07/2016
Chief Operating Officer 62 31/03/2017

Composition of the Board of Directors: Constellation Pharmaceuticals, Inc.

Director TitleAgeSince
Director/Board Member - 14/07/2021
Director/Board Member - -

Company details: Constellation Pharmaceuticals, Inc.

Constellation Pharmaceuticals, Inc.

215 First Street

02142, Cambridge

+

http://constellationpharma.com
address Constellation Pharmaceuticals, Inc.(CNST)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.85%-1.67%+43.33%+85.71% 41.32B
Weighted average by Cap. -2.30%-1.21%+43.56%+88.58%
  1. Stock Market
  2. Stocks
  3. CNST Stock
  4. Company Constellation Pharmaceuticals, Inc.